For a San Diego biotech or life sciences company, a useful 21 CFR Part 11 discussion begins with a record: where it comes from, how it changes, who reviews it and how the organization retrieves it later. An electronic lab notebook, laboratory information management system or quality platform can support several different workflows. The software label alone does not establish the regulatory scope. This guide helps quality, regulatory, laboratory and IT stakeholders organize a readiness review around the electronic records and signatures their operation actually relies on.
Start with applicability, predicate rules and intended use
FDA’s Part 11 scope and application guidance ties the discussion to applicable recordkeeping requirements and how electronic records are used. A predicate rule is an underlying requirement governing the record. The guidance also describes FDA’s enforcement approach; it does not remove the need to meet applicable predicate-rule obligations.
Ask your quality and regulatory team to identify the records and requirements before IT sets the review boundary. Separate exploratory research workflows from records used in regulated activities, documenting the actual circumstances instead of assuming either category applies to an entire laboratory. A company operating in Torrey Pines or Sorrento Valley needs the same careful scope decision as a team in Carlsbad: the location helps plan the engagement, while the records and intended use determine the relevant questions.
Map ELN, LIMS and eQMS workflows before assessing features
Build a practical system inventory that includes the electronic lab notebook (ELN), laboratory information management system (LIMS), electronic quality management system (eQMS), instrument software and any integrations involved in the selected workflow. Record each system owner, intended use, administrator and data destination. Include spreadsheets and manual exports where they form part of the process.
For an illustrative biotech team transferring instrument output into a quality record, trace the original information, the export, the review and the retained result. Identify which version is authoritative and where staff make decisions. This map helps your team ask focused questions about interfaces, access and evidence. It also prevents an assessment from overlooking a handoff simply because two applications are supplied by different vendors.
Review record controls and audit trails with representative examples
21 CFR 11.10 describes controls for closed systems, including validation, authorized access, record copies, retention and secure, time-stamped audit trails. Record changes should not obscure earlier information. Use the applicable requirements and FDA guidance to define what your assessment will examine.
As a practical review exercise, choose an approved test example and follow its creation, correction and retrieval. Ask who can change the record, whether the history remains available and how the reviewer obtains a complete copy. Have the system owner demonstrate the configured behavior instead of relying only on a product brochure. Record any unanswered question with an owner and the evidence needed to resolve it.
Electronic signatures need a defined meaning and review process
Under 21 CFR 11.50, signed electronic records identify the signer, signing date and time, and the meaning of the signature. Treat review, approval and authorship as distinct actions when designing the workflow. Other Part 11 signature requirements also need to be evaluated for the relevant system.
For planning purposes, list who may perform each action and how role changes are approved. Ask the responsible stakeholders to walk through a normal approval, a rejected record and an employee departure. Include system configuration and written procedures in the conversation. A signature feature can be part of the solution, but the assessment should address how people use it and how that use is documented.
Validation evidence, CSV and the scope of FDA’s CSA guidance
Computerized system validation (CSV) and computer software assurance (CSA) are useful search terms, but their context matters. FDA’s February 2026 Computer Software Assurance guidance addresses software used in medical device production or the quality management system. It should not be presented as a blanket replacement for every biotech validation obligation or for Part 11.
Ask the quality owner which approach and evidence are appropriate to the specific system and intended use. Gather existing requirements, supplier documentation, test records, deviations and change history. Identify what is available, what needs review and what remains to be produced. Keep technical assessment, validation execution and formal approval responsibilities explicit in the project scope.
Cloud platforms and external partners belong in the system boundary
A San Diego life sciences team may work with a hosted platform, instrument supplier or external research partner. Map the handoff and administrative responsibility for each connection. A hosted environment still needs a clear business owner who can explain account changes, exports, incident escalation and the information available when the relationship ends.
During readiness planning, ask the provider for the documentation relevant to your intended use and confirm which configurations your organization controls. Discuss how the team would retrieve its information and who would coordinate a recovery exercise. For clinical investigation workflows, consult the applicable FDA electronic systems questions and answers with your regulatory stakeholders. General IT maintenance and regulated-record review should have coordinated, clearly assigned responsibilities.
Build a readiness package your quality and IT teams can use
Start the discussion with a concise package: system inventory and intended use; the record workflows selected for review; responsible quality, regulatory and IT contacts; available procedures and validation evidence; and known issues or upcoming changes. Provide summaries first. Credentials, sensitive production records and confidential research data do not belong in an initial website inquiry.
Agree on the output before work starts. A useful technical gap review can identify observations, missing evidence, questions for quality review and proposed remediation owners. Prioritize changes according to the organization’s assessment of risk and business impact. Separate the findings from implementation work, then define how completed actions will be verified. This gives the company a usable plan rather than an unassigned list of concerns.
Part 11 readiness support for San Diego biotech and life sciences
Does every ELN need the same assessment? Scope depends on its use and the applicable requirements. Can a software vendor’s feature list establish your company’s compliance? It is an input to the review, not a determination about your complete workflow. Does a readiness engagement provide FDA approval? No; it supports assessment and remediation planning within an agreed scope.
Mytek Pros helps San Diego County organizations discuss their electronic record environment, technical controls and evidence gaps alongside quality and regulatory stakeholders. Explore our 21 CFR Part 11 readiness service or request an assessment discussion. Include your systems, intended use, record types and objectives so the first conversation can focus on the review your team needs.